Background: Acute promyelocytic leukemia (APL) is distinguished from other forms of leukemia by its association with bleeding diatheses. All-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ), which have been effectively used in the treatment of the APL, promptly improve coagulation/bleeding syndromes by regulating the expressions of tissue factor (TF) and thrombomodulin (TM). We have previously shown a novel activity of auranofin (AF), in that it induced apoptosis and differentiation of NB4 cells. To study whether AF also possesses similar anticoagulant effects to those of ATRA and As 2 O 3 , its effects on the expressions of TM and TF were investigated. Methods: NB4 cells derived from APL were incubated with 1μM of AF. After incubation for 12, 24 and 48 hours, the AF-regulated expressions of TM and TF were analyzed by RT-PCR, Northern blot and Western blot. The assay for the TM antigen on the cell surface was performed using a flow cytometry. Results: The expression of the TM gene was increased for upto 12 hours after the AF treatment, but no change was observed in the expression of the TF gene. Western blot analysis also demonstrated that AF increased the level of TM proteinin a time-dependent manner. FACS data showed the TM antigen on the cell surface to gradually increase for upto 48 hours in AF-treated cells.
. The structure of AF.
INTRODUCTION
Acute promyelocytic leukemia (APL) presents the abnormal accumulation of promyelocytic cells caused by a failure in cell differentiation. The character of APL is a reciprocal chromosomal translocation [t (15; 17) ], which leads to the fusion of the genes encoding promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARα). The resultant PML-RARα fusion protein plays an important role in the pathogenesis of APL. 1) The APL is also characterized by bleeding diatheses which usually become more serious during chemotherapy. Bleeding diatheses in APL are generally attributed to disseminated intravascular coagulation (DIC) and hyperfibrinolysis. In fact, APL patients have showed elevated levels in thrombin-antithrombin complex, prothrombin fragment 1+2, fibrinopeptide A and elastase, and decreased levels in protein C and coagulation inhibitors. 2, 3) Thrombomodulin (TM) is the specific cell surface receptor that forms a complex with thrombin. The thrombin-TM complex activates protein C that forms a complex with its cofactor protein S. The protein C-protein S complex proteolytically degrades factor Va and VIIIa, and thereby suppresses thrombin generation. In contrast, tissue factor (TF), an essential cofactor for the activation of the extrinsic coagulation pathway, combines with coagulation factor VII or VIIa and activates factor X which contributes to the thrombin generation.
Because the pharmacologic high dose of alltrans retinoic acid (ATRA) induces neutrophilic differentiation of the APL cells both in vitro and in vivo, the differentiation-inducing therapy with ATRA has been effectively used in APL patients. Recently, As 2 O 3 has also been used as an effective therapeutic agent in APL patients including relapsed cases that are resistant to ATRA treatment. 4, 5) It has been reported that the ATRA or As 2 O 3 treatment in APL patients improve bleed-ing symptoms through significantly decreasing procoagulant activity and TF expression. 6, 7) Auranofin (AF; 2,3,4,6-tetra-o-acetyl-1-thio-β-D-glucopyranosato-S-(triethyl-phosphine) gold) is a thiol-reactive gold (I) compound ( Fig. 1 ). It has been widely used in the treatment of rheumatoid arthritis. Recent studies have reported the antiinflammatory mechanism of the AF, and demonstrated that it inhibits NF-κB activation by blocking IκB kinase activity and thereby reduces the gene expression of proinflammatory cytokines such as IL-1β and TNF-α. 8, 9) Our previous study showed that the AF possesses the novel activity to induce apoptotic cell death and to synergistically enhance differentiation of APL cells in a combined treatment with ATRA. 10, 11) These findings suggested that the AF had the potential as a new drug for APL therapy.
To study whether AF has an anticoagulant property, we investigated the effect of the AF on expressions of TM and TF in APL-derived NB4 cell line in this paper.
MATERIALS AND METHODS

Cell culture
NB4 human acute promyelocytic leukemia cells were grown in RPMI 1640 medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). To study the regulation of TM and TF expression, the NB4 cells were plated at a density of 2×10 5 /mL and stimulated with 1μM AF for various durations.
Total RNA preparation and RT-PCR
Total cellular RNA was extracted by using RNAzol B solution (Tel-test Inc., Friendswood, TX), according to the procedure recommended by the manufacturer. The RT-PCR was carried out as the same procedure described in the previous report. 12) In brief, 2μM total RNA was reversetranscribed for 30 minutes at 42 o C in 1×PCR buffer containing 5mM MgCl 2 , 1mM dNTPs, RNase inhibitor, random hexamer, and 0.1U/μL AMV reverse transcriptase in a total volume of 50 μL. A 2μL aliquot of the RT product was amplified in a total volume of 50μL. The amplification was performed 30 cycles under the following reaction conditions: 5mM MgCl 2 , 1mM dNTPs, 10pmol TM or TF primers, 13) 0.1U/μL
Taq DNA polymerase (denaturation at 95 o C for 1 minute, annealing at 55 o C for 1 minute and extension at 72 o C for 1 minute), and then a 10μL aliquot of the PCR product was separated electrophoretically on a 1.5% agarose gel and stained with ethidium bromide.
Northern blot analysis
Prepared RNA samples (10μg) were separated electrophoretically on a 1.2% agarose-formaldehyde gel, and transferred to a nylon membrane (Boehringer Mannheim, Mannheim, Germany). The hybridization was performed at 45 o C in ExpressHyb hybridization solution (Clontech, palo Alto, CA) for 2 hours with the probe for TM into which DIG-11-dUTP nucleotides were incorporated. The transcripts were analyzed by using DIG chemiluminescent detection kit (Boehringer Mannheim, Germany).
Western blot analysis
The cells were washed twice with phosphatebuffered saline (PBS), and then lysed in RIPA buffer (50mM Tris, 150mM NaCl, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1mM phenylmethylsul-fonyl fluoride, 100μM/mL trypsin inhibitor, 50 μM leupeptin, and 100μM antipain, pH 8.0).
After the protein concentration of each lysate was determined, equal amounts of the samples (50μg) were separated on a 12% SDS-polyacrylamide gel. After electrophoresis, the gel was transferred to a nitrocellulose membrane in an XCell TM blot module (Novex, San Diego, CA). The proteins of interest were detected with rabbit polyclonal anti-TM antibody (Santa Cruz Biotechnology, Santa Cruz, CA) using an enhanced chemiluminescence detection kit (Amersham, Buckinghamshire, UK).
FACS analysis
The NB4 cells were incubated with or without 1μM of AF for 12, 24 and 48 hours and washed twice with buffer A (PBS, 0.1% sodium azide, 1% heat-inactivated FBS). After being resuspended in buffer A, 50μL of aliquot (1×10 6 cells) was incubated with antibody against TM or isotype control rabbit IgG. Following incubation on ice for 30 minutes, the cells were washed three times and further incubated with fluorescein isothiocyanateconjugated anti-rabbit IgG for 30 minutes on ice. The incubated cells were washed again, resuspended in 500μL of buffer A containing propidium iodide, and then analyzed on a FACScan flow cytometer (BD Biosciences, San Diego, CA).
RESULTS
The effect of AF on TM and TF gene expressions
To examine the regulation of procoagulant factors by AF, NB4 cells were incubated with 1μM of AF for 12 and 24 hours, and the expressions of TM and TF were investigated. According to RT-PCR data, the level of TM mRNA was increased by AF within 12 hours, while TF mRNA level was not changed until 24 hours ( Fig.  2A) . Up-regulation of TM gene expression was also confirmed by Northern blot analysis in which AF enhanced a specific 3.7kb band correspondent to TM transcript (Fig. 2B) . 
The enhancement of TM antigen level by AF
To investigate whether the increased TM mRNA level was consistent with TM protein level, TM antigens were detected by Western blot analysis. When the cells were treated with AF, a 75kD band correspondent to TM protein was gradually increased until 48 hours (Fig. 3) .
TM, high affinity thrombin receptor, is an integral membrane protein. Therefore, we further verified the increased TM antigen on cell surface by using a flow cytometry method. As shown in Fig. 4 , the treatment of NB4 cells with 1μM of AF enhanced cell surface TM antigen level in a time-dependent manner. These findings indicate that the AF can diminish a coagulant reaction.
DISCUSSION
In this paper, we demonstrated that AF upre- gulated TM expression in NB4 cells. The induction of TM expression occurred within 12 hours and was accompanied by the increase of transcript level. We also found the enhancement of cell surface TM antigen, which forms a complex with thrombin. These results indicate that the AF exerts antithrombotic activity.
The AF has been widely used in the treatment of rheumatoid arthritis, which is based on its antiinflammatory and immunosuppressive properties. 14) Because it reacts with thiol and/or selenol groups, the AF also potently inhibits mitochondrial thioredoxin reductase (TrxR), which is a selenocysteine-containing enzyme. 15) Recent reports have showed that the AF induces cytochrome c release into cytoplasm by inhibiting mitochondrial TrxR 16, 17) and ultimately leads to apoptotic cell death. 18) In addition, we have found that the AF exhibits dual effects on apoptosis and differentiation of APL cells. This drug not only induced apoptotic cell death via ROS generation and p38 MAP kinase activations but also synergistically enhanced the differentiation of APL cells in a combined treatment with ATRA. 10, 11) On the other hand, As 2 O 3 has been effectively treated for management of APL patients because it has a proapoptotic activity and a partial differentiation-inducing activity. 4) The As 2 O 3 also improves the coagulant problems in APL patients by regulating TM and TF expression. 7) Since both AF and As 2 O 3 are thiol-reactive organometallic compounds and act in a similar manner on apoptosis and differentiation of APL cells, we thought that AF might have similar functions to that of As 2 O 3 in blood coagulation, and investigated its effect on TM and TF expressions. For the first time, a novel antithrombotic property of AF is identified in the present study, which suggests that the AF might improve thrombotic complications of APL patients. However, further studies showing the effects of AF on other procoagulant/anticoagulant factors will be required. 
